{
  "docId": "019dd923-622c-750b-8b96-fcb164354e3e",
  "docSlug": "86ed72671dc5",
  "documentTitle": "PeptiDream, Inc. (4587 JP)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-11-07 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 14,
  "pageCount": 22,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a table of targets followed by a narrative critique of management's credibility and financial performance.",
  "elementsJson": [
    "data_table",
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b96-fcb164354e3e/14",
  "deckHref": "/decks/019dd923-622c-750b-8b96-fcb164354e3e",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b96-fcb164354e3e.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b96-fcb164354e3e#slide-14",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "These targets are fast approaching their due dates, and they defy not only PeptiDream’s own track record, but also industry success rates and our forecasts.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-14dd-72ca-b97b-463569269521",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.762,
        "x": 0.119,
        "y": 0.485
      },
      "kind": "paragraph",
      "text": "To perpetuate PeptiDream’s reputation for innovation, company executives advance prospects that are entirely divorced from the current realities of the business.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2eb75241-bb2c-44e6-aaf6-30532863b9da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.762,
        "x": 0.119,
        "y": 0.327
      },
      "kind": "paragraph",
      "text": "These targets are fast approaching their due dates, and they defy not only PeptiDream’s own track record, but also industry success rates and our forecasts.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96577e43-a5a3-4f1d-824a-95687e49e069",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "In the near future, the operating margin will reach around 80%. — Toshiyuki Iwata, PeptiDream Investor Relations Director",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-14dd-72ca-b97b-480c7243d0ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.762,
        "x": 0.119,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "Footnotes 24-30",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52571f78-bb13-46ba-b3f1-6258bdc3b91e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.612,
        "x": 0.188,
        "y": 0.12
      },
      "kind": "table",
      "text": "Medium-term targets (by the end of June, 2022) 1. Bringing to market new drugs (approval and sales) 1 or more 2. Number of companies with which the Company has discovery and optimization agreements 25 or more 3. Number of companies to which the Company reaches PDPS non-exclusive technology license agreements 8 or more 4. Number of projects for which clinical trials begin 10 or more 5. Number of employees at the end of June 30, 2022 170 or more",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06d7efbb-9b7e-4f66-a205-c64978d66081",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.762,
        "x": 0.119,
        "y": 0.45
      },
      "kind": "title",
      "text": "PeptiDream’s Bold Claims and Increased Spending Try to Buy Time For Future Success",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1497d83b-1c30-4af0-be4b-8b3dd076cc45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.335,
        "x": 0.208,
        "y": 0.095
      },
      "kind": "title",
      "text": "Figure H: 2022 Medium-Term Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c4c334c-0218-4721-b914-ffc2a04fd7db",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "68f274b0-1a76-40e3-87d2-21a33e4d8de4",
      "evidence": "The slide presents a table with data on PeptiDream's medium-term targets.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "e0bfd391-8c1d-4c9d-a6d0-8cdee8a66091",
      "evidence": "Contrasting management claims against historical financial reality and operational performance.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 14,
      "from": 14,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7bc8e6b1-a1ce-42a2-a4fd-18d7bcb93922",
      "evidence": "PeptiDream's bold claims and increased spending",
      "position": 1,
      "objective": "Highlight cost of inaction for PeptiDream",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}